Qu Biologics.png
Results from Qu Biologics’ Crohn’s Disease RESTORE Trial Selected for Oral Presentation at ECCO 2021
June 09, 2021 09:00 ET | Qu Biologics, Inc.
VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- Qu Biologics Inc., a clinical stage biopharmaceutical company developing Site Specific Immunomodulators (SSIs), a novel platform of...
Emergen logo.png
Human Microbiome Therapeutics Market Size Worth USD 1,098.4 Million by 2027 | Rising Government Initiatives In Microbiome Research Projects And Increasing Drug-Related Side Effects Are Driving The Industry Growth, says Emergen Research
March 02, 2021 08:59 ET | Emergen Research
Vancouver, British Columbia, March 02, 2021 (GLOBE NEWSWIRE) -- The global Human Microbiome Therapeutics Market is forecasted to be worth USD 1,098.4 Million by 2027, according to a current analysis...
Trivedi Global, Inc. Announces Research by Gopal Nayak on The Potential Benefits of Biofield Energy Treated Antineoplastic Chemotherapy Drug
June 04, 2019 12:26 ET | Trivedi Global, Inc.
Las Vegas, Nevada, US, June 04, 2019 (GLOBE NEWSWIRE) -- Gopal Nayak, today released research results on the beneficial impact of biofield energy treatment on improving physicochemical properties of...
Nash Pharmaceuticals Announces Positive Pre-Clinical Results For Its Lead Compound NP-178 in a New Study for Crohn’s Disease
December 03, 2018 07:00 ET | Breathtec Biomedical Inc.
VANCOUVER, British Columbia, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Nash Pharmaceuticals Inc., a wholly owned subsidiary of Breathtec Biomedical Inc. (CSE: BTH) (CNSX: BTH) (FRANKFURT: BTI)...